The agreement refers to ‘Azodyl’, a patented, 100% natural, probiotic dietary supplement which is used to reduce azotemia in dogs and cats with moderate to severe renal failure.
Kibow aims to use a major portion of the $2.4m funding for testing a similar, patented, probiotic dietary supplement intended for human consumption.
The product is called ‘Kibow Biotics’, an orally consumable, enteric-coated gel cap product composed of food-grade microbes (‘Probiotics’) helps in improving the quality of life in chronic kidney failure (CKF) patients.
The drug gets metabolized and the uremic toxins get diffused into the bowel as a consequence of increased levels of these toxins in the blood.
Kibow’s is set to start a human clinical trials involving dialysis and pre-dialysis patients at Mayo clinic, Rochester.